EGLN1 and cancer: Specifically, HISLA inhibits the hydroxylation and degradation of HIF‐1α by blocking the interaction of HIF‐1α with PHD2.[12] Collectively, our findings suggest a new mechanism for the regulation of glycolysis by MALAT1 in cancer progression.